Beta-alanine performance is supported by decades of clinical research, but paresthesia and dosing requirements have consistently limited its reach—ruling out certain formats and turning away consumers who could otherwise benefit. CarnoSyn® 4X was developed to solve those problems.

Join Mark LeDoux, CEO and Chairman of Natural Alternatives International, as he discusses the science and clinical evidence behind CarnoSyn® 4X, and what that means for brands looking to expand their formulations, their claims, and their audience.